PMID- 35968590
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20221231
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 43
IP  - 6
DP  - 2022 Jun 14
TI  - [Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature 
      review].
PG  - 475-480
LID - 10.3760/cma.j.issn.0253-2727.2022.06.006 [doi]
AB  - Objective: To study the clinical, histopathological, and genetic features of 
      large B-cell lymphoma (LBCL) with IRF4 rearrangement. Methods: Six patients 
      presenting at our center between December 2017 and October 2021 were evaluated by 
      pathological examination, fluorescence in situ hybridization, and next-generation 
      sequencing. The relevant literature was reviewed. Results: 1 in circleThe study sample 
      included three males and three females with a median age of 33 years. Three 
      tumors were in the tonsils, two in the lymphoid nodes, and one in the dorsal 
      lump. All patients were treated using the RCDOP (rituximab, cyclophosphamide, 
      liposomal doxorubicin, vincristine, prednisone) regimen. All of them were alive 
      at the time of follow-up in November 2021. 2 in circleMicroscopic examination showed an 
      entirely follicular pattern in one case and an entirely diffused pattern in 5 
      cases. The tumor cells were medium to large, and most of the lesions were 
      dilatative with brisk mitotic activity (n=five cases) and no starry sky pattern 
      (n=6 cases) . 3 in circleFour cases exhibited a GCB phenotype, and the other two exhibited 
      a non-GCB phenotype. All of the cases were positive for CD20, PAX-5, MUM, and 
      BCL6, and negative for CD5. Moreover, CD10, BCL2, and c-MYC were positive in 4, 
      3, and 2 cases, respectively.4 in circleIRF4 gene rearrangement was identified in all 
      cases, BCL6 gene rearrangement was detected in 5 cases, and 2 cases were 
      positive. BCL2 and MYC gene rearrangement were performed in 5 cases, all 
      negative. ⑤Three paraffin tissue samples were used for next-generation 
      sequencing, and lymphoma-related gene mutations such as IRF4, TP53, IGLL5, and 
      MYD88 were detected in 3 cases. Conclusions: LBCL with IRF4 rearrangement is a 
      rare entity with unique clinical, pathological, and genetic characteristics. This 
      entity's pathogenesis, treatment options, and long-term prognosis still need to 
      be explored further.
FAU - Yu, Y
AU  - Yu Y
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
FAU - Sun, Q
AU  - Sun Q
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
FAU - Li, C W
AU  - Li CW
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
FAU - Jia, Y J
AU  - Jia YJ
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
FAU - Liu, W
AU  - Liu W
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
FAU - Wang, T Y
AU  - Wang TY
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
FAU - Lyu, R
AU  - Lyu R
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
FAU - Yan, Y T
AU  - Yan YT
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
FAU - An, G
AU  - An G
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
FAU - Qiu, L G
AU  - Qiu LG
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
FAU - Zou, D H
AU  - Zou DH
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
FAU - Yi, S H
AU  - Yi SH
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin 300020, China.
LA  - chi
GR  - 81970187、82170193、81920108006、81900203/National Natural Science Foundation of 
      China/
GR  - CAMS-2017-I2M-3-018、CAMS-2019-I2M-2-009/CAMS Innovation Fund for Medical Science/
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
SB  - IM
MH  - Chromosome Aberrations
MH  - Female
MH  - Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Male
MH  - Proto-Oncogene Proteins c-bcl-2/genetics
MH  - Proto-Oncogene Proteins c-bcl-6/genetics
PMC - PMC9800220
OTO - NOTNLM
OT  - B-cell lymphoma
OT  - Fluorescence in situ immunohybridization
OT  - Gene, IRF4
OT  - Next-generation sequencing
OT  - Pathology
COIS- 利益冲突 所有作者声明无利益冲突
EDAT- 2022/08/16 06:00
MHDA- 2022/08/17 06:00
PMCR- 2022/06/01
CRDT- 2022/08/15 04:18
PHST- 2022/08/15 04:18 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
PHST- 2022/06/01 00:00 [pmc-release]
AID - cjh-43-06-475 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2022.06.006 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):475-480. doi: 
      10.3760/cma.j.issn.0253-2727.2022.06.006.